FT. LAUDERDALE, Fla., Nov. 22, 2004 (PRIMEZONE) -- Sunwin International Neuturaceuticals, Inc. (OTCBB:SUWN) is pleased to announce the release of a research report prepared by Nadeem Naqvi of Investology Inc. Investology Research was ranked as the No.3 best performing independent research firm by Business Week in July 2004. Nadeem Naqvi, formerly the Head of Research for Morgan Stanley Pakistan Fund's advisory company and a member of the Merrill Lynch Pakistan research team, has over twenty years' experience in the international financial services industry. He is a member of The Association for Investment Management & Research (AIMR).
The report can be accessed via First Call.
The following is a brief excerpt of the report:
Investment Highlights
We are initiating coverage of Sunwin International Neutraceuticals Inc. (OTCBB:SUWN) with a positive rating and a 12-month price target of $0.52, implying a potential upside of over 135% from current levels. SUWN is engaged in the production and sale of herbal and traditional Chinese medicinal products ranging from natural sweeteners and herbal extracts to organic veterinary medicines and additives. Our positive rating is based on expectations of strong top line growth through to 2006 and improving margins that should lead to over 100% net profit growth in 2005 and 27% in 2006. This is a high risk investment only suitable for investors with high risk tolerance.
-- SUWN has positive and growing cash flows, a low debt
balance sheet, comfortable current ratio of 1.75 and
achieved an ROE of 12.3% in fiscal 2004.
-- We believe that SUWN is well placed to capitalize
on the rising global interest in herbal/organic
products, where United Nations Council for
Trade and Development Biotrade Initiative forecasts
a growth rate of 6.5% p.a. to $40 billion market by 2011.
-- In 2002, worldwide demand for stevioside, the key
ingredient for beetroot based natural sweeteners,
exceeded 1,200 tons and China accounted for 80%
of worldwide supply of which 200 tons, or 16% of
worldwide production, was accounted for by SUWN.
SUWN's operating subsidiary, with nearly 300 employees, has considerable experience and expertise in the herbal and organic veterinary formulations and has won awards and recognition in China as an innovator in its field.
To view a full-length report, please visit:
http://www.investologyinc.net/pages/8/index.htm or www.sunwin.biz.
About Investology, Inc.
Investology's Research team focuses on six industry sectors: Financial Services, Real Estate, Technology, Healthcare, Energy, and Diversified Industrials. We focus on micro, small and mid-cap stocks, which lack coverage by traditional research firms or investment banks. Investology Inc., is headquartered in Virginia, with an office in Toronto, Canada. For more information, please visit http://www.investologyinc.net
This announcement contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. Investology Inc. received $3,000 from a third party to write and distribute Sunwin International Neutraceuticals, Inc. report. The analyst hereby certifies that he does not own any share in Sunwin International Neutraceuticals, Inc. Investology Inc. does not have any investment banking relationship with Sunwin International Neutraceuticals, Inc
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. ("Sunwin") is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, nutraceutical products, natural sweetener (beet sugar), and animal medicine prepared from 100% organic herbal ingredients. Sunwin International Neutraceuticals, Inc. is doing business in China through its subsidiary, Shandong Qufu Natural Green Engineering Company, Limited ("Qufu"). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more information about Sunwin, please visit http://www.sunwin.biz.
Safe Harbor Statement
Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.